Related Experiment Video
Updated: Jan 18, 2026
Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty
Published on: January 28, 2020
Diagnostic and prognostic value of systemic immune-inflammation index for heart failure: a systematic review and
Jiajun Yu1, Tian Zuo2, Sihan Peng1
1Traditional Chinese Medicine Department, The Eighth Affiliated Hospital, Sun Yat-sen University (FuTian, Shenzhen), Shenzhen, Guangdong, China.
Insights
The Systemic Immune-Inflammation Index (SII) is not linked to heart failure incidence but is a reliable predictor of increased mortality risk in heart failure patients.
Area of Science:
- Cardiology
- Immunology
- Biomarker Research
Background:
- The Systemic Immune-Inflammation Index (SII) has shown potential links to heart failure (HF) incidence and prognosis.
- Existing research has not fully clarified the association between SII and HF outcomes.
Purpose of the Study:
- To systematically investigate the association between SII and the incidence and clinical outcomes of HF patients.
- To conduct a meta-analysis of existing studies to determine the prognostic value of SII in HF.
Main Methods:
- A comprehensive literature search was performed across major databases (PubMed, Embase, Web of Science, Cochrane Library) up to July 2024.
- Meta-analyses were conducted using Review Manager and STATA, assessing incidence and mortality rates using risk ratios (RR) and 95% confidence intervals (CIs).
- Sensitivity and subgroup analyses were performed to evaluate the robustness and heterogeneity of the findings.
Main Results:
- Fifteen studies involving 77,917 patients were analyzed.
- No significant association was found between SII and HF incidence (RR = 1.22, 95%CI: 0.92-1.62, p = 0.16).
- Elevated SII was significantly correlated with increased HF mortality risk (RR = 1.44, 95%CI: 1.29-1.61, p < 0.00001), unaffected by various subgroup factors except country for incidence.
Conclusions:
- The Systemic Immune-Inflammation Index (SII) is a valuable prognostic biomarker for heart failure patients.
- SII can provide crucial insights for clinical decision-making in managing heart failure.
Background:
Increasing evidence has indicated the potential correlation between Systemic Immune-Inflammation Index (SII) and the incidence and prognosis of patients with heart failure (HF). However, the association remains unraveled in the existing research.
Methods:
A literature search was systematically conducted across PubMed, Embase, Web of Science, and the Cochrane Library from their respective inceptions to July 2024, aiming to identify studies investigating the association between SII and both the incidence and clinical outcomes of HF patients. The primary outcomes included incidence and mortality rates, which were assessed using risk ratios (RR) and corresponding 95% confidence intervals (CIs). To assess the robustness of the findings and to identify potential sources of heterogeneity, sensitivity analyses and subgroup analyses were conducted. Meta-analyses were carried out using Review Manager (v5.4) and STATA (v15.0).
Results:
Fifteen studies comprising 77,917 patients were included. The pooled data demonstrated no significant association between SII and the incidence of HF (RR = 1.22, 95%CI: 0.92-1.62; p = 0.16). However, a significant correlation was identified between elevated SII and increased mortality risk (RR = 1.44, 95%CI: 1.29-1.61; p < 0.00001). Furthermore, subgroup analyses revealed the association between SII and mortality in patients with HF was not influenced by sample size, age, country, study design, or ejection fraction. In contrast, the association between SII and incidence of HF was affected by country, while no significant effect was observed in the other subgroups.
Conclusion:
As a reliable biomarker, SII exhibits significant efficacy in prognostic evaluation for HF patients and provides valuable insights to inform clinical decision-making in the HF population.
Systematic Review Registration:
https://www.crd.york.ac.uk/PROSPERO/myprospero, PROSPERO CRD42024582003.
More Related Videos
06:38Simultaneous 3D Analysis of Cardiac Damage and Immune Response in Reperfused Acute Myocardial Infarction Using Light Sheet Fluorescence Microscopy
Published on: September 26, 2025
08:51Author Spotlight: Integrated Multi-Omics Analysis for Unveiling Multicellular Immune Signatures in Clinical Heart Attack Cohorts
Published on: September 20, 2024
Related Concept Videos
01:22Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies
01:19Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
01:21Myocarditis I: Introduction
01:30Heart Failure IV: Classification and Diagnostic Evaluation
01:29Heart Failure II: Pathophysiology
01:30Acute Coronary Syndrome III: Diagnostic Studies